ROIV’s mosliciguat advances to phase III in PH-ILD
Phase IIb PHocus study in PH-ILD said mosliciguat delivered a record 56.3% reduction in PVR, with significant and sustained six-minute walk distance improvements, and robust safety and tolerability. Benefits were consistent across subgroups.
3% reduction in PVR, along with significant and sustained improvements in six-minute walk distance and robust safety and tolerability. Benefits were consistent across subgroups, supporting rapid advancement to phase III.